newsfilter
← Latest News
GlobeNewswire·

LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102